Eli Lilly's EPS grew significantly in Q3, projected to continue at 71.7% annually. Novo Nordisk and Vertex Pharmaceuticals are highlighted as attractive growth stocks due to market advantages, product success, and strong financial projections.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing